CAR-T Funding Report 2025 | Over 1,944 CAR-T Therapies in Development as Global Collaborations Reach New Heights - ResearchAndMarkets.com

The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2025" has been added to ResearchAndMarkets.com's offering.

In recent years, the CAR-T industry has experienced a remarkable surge in funding. CAR-T therapies have catalyzed a funding boom, with start-ups being richly supported by investors and large pharmaceutical companies eager to penetrate this burgeoning area of regenerative medicine.

Globally, over 170 companies are actively developing CAR-T products, with 1,944 therapies in various development stages. Companies have engaged in approximately 110 collaboration agreements to advance their CAR-T candidates, with only 38 of these deals publicly disclosing a collective value of $23.58 billion. The estimated value for all collaborations could ascend to $67.9 billion.

This industry garners significant interest from venture capitalists worldwide. Since 2014, 89 CAR-T companies have raised $7.7 billion in venture capital, paving the way for technological advancement and diversification into therapies for hematological and other cancers. Despite a slow IPO market in 2024, exemplified by Kyverna Therapeutics' $319 million raise, 42 companies have gone public since 2014, amassing $6.4 billion to enhance their platforms and strategies.

Currently, the industry boasts 72,418 patent records, with 452 patents granted, highlighting that major pharmaceutical companies are eager to license these innovations. Over ten years, 91 CAR-T licensing deals have reached a valuation of $6.3 billion, a figure expected to rise dramatically over the next decade.

The year 2023 witnessed a resurgence in dealmaking, although 2024 saw a dip in mergers and acquisitions (M&A) with merely two consummated deals. Significant M&A activity may not return in 2025. However, further deals are anticipated as pharmaceutical companies seek to invest their reserves. M&A deals have played a pivotal role in industry financing, generating a total of $97.4 billion.

Across varying deal types-including IPOs, licensing, collaborations, and M&A transactions-the CAR-T sector has amassed over $141.2 billion. With many deals undisclosed, estimates suggest the industry financing might soar to $281.7 billion.

Globally Approved CAR-T Therapies

Since 2017, 13 CAR-T cell therapies have been commercialized across global healthcare markets. Seven therapies received U.S. FDA approval, with subsequent global endorsements. China's National Medical Products Administration has validated four therapies, while India's Central Drugs Standard Control Organisation approved two.

The existing 13 therapies are exclusively for blood cancer treatment, serving less than 5% of global cancer patients. There are currently around 1,944 clinical trials aimed at blood and solid tumors, driven by an impressive 90% remission rate in approved therapies.

CAR-T Market Overview

The comprehensive 220-page CAR-T market funding report reviews global investment trends within the sector, detailing financing rounds, IPOs, M&A, strategic alliances, and profiling 78 leading competitors.

• Financing Rounds
• IPOs
• Asset Agreements
• Strategic Partnerships
• Co-Development Agreements
• M&A Transactions
• Company Profiles for CAR-T Market Competitors

Benefits of this Report:

• Quantify investments in the CAR-T sector
• Identify well-capitalized entities
• Scout potential partnerships and collaborations
• Comprehend partnerships and co-development programs
• Identify M&A trends within the industry

To summarize, CAR-T entities, from innovative start-ups to extensive enterprises, have engaged in numerous financial endeavors worth hundreds of billions. This report reveals critical insights into the financial dynamics shaping the industry, showcasing capital allocations and strategic opportunities for growth.

Key Topics Covered:

• Uptake of CAR-T Therapies, Full Year 2017 to 2024
• CAR-T Funding: An Overview
• IPO Funding Invested in CAR-T Companies
• CAR-T Licensing Deals
• CAR-T Collaboration Deals
• CAR-T Merger & Acquisition (M&A) Deals
• Profiles of Companies Included in the Report

Companies Featured

• A2 Biotherapeutics
• Adicet Bio
• AffyImmune Therapeutics
• Allogene Therapeutics
• Arcellx
• Arsenal Biosciences
• Artiva Biotherapeutics
• Atara Biotherapeutics
• Autolus Therapeutics
• AvenCell Therapeutics
• Bellicum Pharmaceuticals
• BioNTech
• Biosceptre
• Cabaletta Bio
• Capstan Therapeutics
• Cargo Therapeutics
• Caribou Biosciences
• Carina Biotech
• CARsgen Therapeutics
• Cellares
• Cellular Biomedicine Group
• Celularity
• Celyad Oncology
• Clade Therapeutics
• Coeptis Therapeutics
• CRISPR Therapeutics
• Currus Biologics
• Dynamic Cell Therapies
• EXUMA Biotech
• Gracell Biotechnologies
• IASO Biotherapeutics
• ImmPACT Bio
• Immuneel Therapeutics
• Inceptor Bio
• Interius BioTherapeutics
• Juno Therapeutics
• Juventas Cell Therapy
• JW Therapeutics
• Kyverna Therapeutics
• Legend Biotech
• Leman Biotech
• Leucid Bio
• Limula
• March Biosciences
• Mnemo Therapeutics
• MPC Therapeutics
• Mustang Bio
• Noile-Immune Biotech
• OneChain Immunotherapeutics
• OriCell Therapeutics
• PeproMene Bio
• Poseida Therapeutics
• Precigen
• Precision BioSciences
• SOTIO Biotech
• Synthekine
• TC BioPharm
• Tessa Therapeutics
• Ucello Therapeutics
• Umoja Biopharma
• Verismo Therapeutics
• Vor Biopharma
• Wugen
• Xenetic Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/kmq25o

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250516588905/en/